Iovance Biotherapeutics updates corporate presentation, reiterates $350M–$370M FY26 guidance

Iovance Biotherapeutics updated its corporate presentation and reiterated FY2026 revenue guidance of $350M–$370M and Q2 guidance of $86M–$88M.Key Highlights:Original SEC Filing: IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ] - 8-K - Jul. 02, 2026This is an AI-powered summary. It may contain inaccuracies. C…

Iovance Biotherapeutics updated its corporate presentation and reiterated FY2026 revenue guidance of $350M–$370M and Q2 guidance of $86M–$88M.

Key Highlights:

Company updated corporate presentation used for healthcare conferences, analysts and stockholders; Exhibit 99.1 attached to 8-K.
Reiterated FY2026 revenue guidance of $350M–$370M and Q2 2026 guidance of $86M–$88M.
Reported cash position of ~$319M as of March 31, 2026, with runway into 2028.
Highlighted commercial footprint: >90 Authorized Treatment Centers and ~1,500+ patients treated with TIL products.
Outlined pipeline and commercial plans including frontline melanoma registrational TILVANCE-301 and fast-track NSCLC lifileucel programs.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.